Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Maryam A.Y. Al-Nesf; Houari B. Abdesselem; Ilham Bensmail; Shahd Ibrahim; Walaa A.H. Saeed; Sara S.I. Mohammed; Almurtada Razok; Hashim Alhussain; Reham M.A. Aly; Muna Al Maslamani; Khalid Ouararhni; Mohamad Y. Khatib; Ali Ait Hssain; Ali S. Omrani; Saad Al-Kaabi; Abdullatif Al Khal; Asmaa A. Al-Thani; Waseem Samsam; Abdulaziz Farooq; Jassim Al-Suwaidi; Mohammed Al-Maadheed; Heba H. Al-Siddiqi; Alexandra E. Butler; Julie V. Decock; Vidya Mohamed-Ali; Fares Al-Ejeh

doi:10.1038/s41467-022-28639-4

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Maryam A.Y. Al-Nesf, Houari B. Abdesselem, Ilham Bensmail, Shahd Ibrahim, Walaa A.H. Saeed, Sara S.I. Mohammed, Almurtada Razok, Hashim Alhussain, Reham M.A. Aly, Muna Al Maslamani, Khalid Ouararhni, Mohamad Y. Khatib, Ali Ait Hssain, Ali S. Omrani, Saad Al-Kaabi, Abdullatif Al Khal, Asmaa A. Al-Thani, Waseem Samsam, Abdulaziz Farooq, Jassim Al-SuwaidiMohammed Al-Maadheed, Heba H. Al-Siddiqi, Alexandra E. Butler, Julie V. Decock, Vidya Mohamed-Ali, Fares Al-Ejeh^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

Original language	English
Article number	946
Journal	Nature Communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-022-28639-4
Publication status	Published - Dec 2022

Access to Document

10.1038/s41467-022-28639-4

Cite this

Al-Nesf, M. A. Y., Abdesselem, H. B., Bensmail, I., Ibrahim, S., Saeed, W. A. H., Mohammed, S. S. I., Razok, A., Alhussain, H., Aly, R. M. A., Al Maslamani, M., Ouararhni, K., Khatib, M. Y., Hssain, A. A., Omrani, A. S., Al-Kaabi, S., Al Khal, A., Al-Thani, A. A., Samsam, W., Farooq, A., ... Al-Ejeh, F. (2022). Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications, 13(1), Article 946. https://doi.org/10.1038/s41467-022-28639-4

@article{fc6a76728b6743f6ba0e1104421505ff,

title = "Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications",

abstract = "COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.",

author = "Al-Nesf, {Maryam A.Y.} and Abdesselem, {Houari B.} and Ilham Bensmail and Shahd Ibrahim and Saeed, {Walaa A.H.} and Mohammed, {Sara S.I.} and Almurtada Razok and Hashim Alhussain and Aly, {Reham M.A.} and {Al Maslamani}, Muna and Khalid Ouararhni and Khatib, {Mohamad Y.} and Hssain, {Ali Ait} and Omrani, {Ali S.} and Saad Al-Kaabi and {Al Khal}, Abdullatif and Al-Thani, {Asmaa A.} and Waseem Samsam and Abdulaziz Farooq and Jassim Al-Suwaidi and Mohammed Al-Maadheed and Al-Siddiqi, {Heba H.} and Butler, {Alexandra E.} and Decock, {Julie V.} and Vidya Mohamed-Ali and Fares Al-Ejeh",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41467-022-28639-4",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Al-Nesf, MAY, Abdesselem, HB, Bensmail, I, Ibrahim, S, Saeed, WAH, Mohammed, SSI, Razok, A, Alhussain, H, Aly, RMA, Al Maslamani, M, Ouararhni, K, Khatib, MY, Hssain, AA, Omrani, AS, Al-Kaabi, S, Al Khal, A, Al-Thani, AA, Samsam, W, Farooq, A, Al-Suwaidi, J, Al-Maadheed, M, Al-Siddiqi, HH, Butler, AE, Decock, JV, Mohamed-Ali, V & Al-Ejeh, F 2022, 'Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications', Nature Communications, vol. 13, no. 1, 946. https://doi.org/10.1038/s41467-022-28639-4

TY - JOUR

T1 - Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

AU - Al-Nesf, Maryam A.Y.

AU - Abdesselem, Houari B.

AU - Bensmail, Ilham

AU - Ibrahim, Shahd

AU - Saeed, Walaa A.H.

AU - Mohammed, Sara S.I.

AU - Razok, Almurtada

AU - Alhussain, Hashim

AU - Aly, Reham M.A.

AU - Al Maslamani, Muna

AU - Ouararhni, Khalid

AU - Khatib, Mohamad Y.

AU - Hssain, Ali Ait

AU - Omrani, Ali S.

AU - Al-Kaabi, Saad

AU - Al Khal, Abdullatif

AU - Al-Thani, Asmaa A.

AU - Samsam, Waseem

AU - Farooq, Abdulaziz

AU - Al-Suwaidi, Jassim

AU - Al-Maadheed, Mohammed

AU - Al-Siddiqi, Heba H.

AU - Butler, Alexandra E.

AU - Decock, Julie V.

AU - Mohamed-Ali, Vidya

AU - Al-Ejeh, Fares

PY - 2022/12

Y1 - 2022/12

N2 - COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

AB - COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

UR - http://www.scopus.com/inward/record.url?scp=85124777237&partnerID=8YFLogxK

U2 - 10.1038/s41467-022-28639-4

DO - 10.1038/s41467-022-28639-4

M3 - Article

C2 - 35177642

AN - SCOPUS:85124777237

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 946

ER -

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Abstract

Access to Document

Other files and links

Fingerprint

Cite this